FDA approval for MOMENTUM trial of percutaneous CHF therapy
Apr 28, 2005 - 12:07:00 AM
Traditional therapies to treat acute CHF include drugs that pull off fluid (diuretics) or cause the heart to pump more strongly (inotropes). In contrast, the Cancion CRS is designed to create an environment that allows the heart to rest while it recovers from an acute decompensation event.
By Orqis Medical, Lake Forest, Calif., [RxPG] Orqis Medical Corporation, developer of the novel and proprietary catheter-based Cancion® cardiac recovery system (CRSTM) to treat congestive heart failure (CHF), today announced U.S. Food and Drug Administration (FDA) unconditional approval for researchers to treat up to 200 CHF patients at 40 centers participating in the company's MOMENTUM pivotal clinical trial.
The Company previously announced conditional FDA approval in January to expand the MOMENTUM clinical investigation from 8 to 40 research centers nationwide.
"The Cancion CRS offers the promise of an exciting new percutaneous therapeutic modality to treat patients suffering from CHF," said Ken Charhut, Orqis Medical's president and CEO. "Unconditional FDA approval to advance the MOMENTUM clinical investigation will allow us to discover its therapeutic potential."
The Cancion CRS is the first therapy for congestive heart failure based on continuous aortic blood flow augmentation to the descending aorta. The MOMENTUM (Multicenter Trial of the Orqis Medical CRS for the Enhanced Treatment of CHF, Unresponsive to Medical Therapy) trial will determine efficacy of the Cancion CRS Therapy to treat patients with acute decompensation resulting from CHF.
Traditional therapies to treat acute CHF include drugs that pull off fluid (diuretics) or cause the heart to pump more strongly (inotropes). In contrast, the Cancion CRS is designed to create an environment that allows the heart to rest while it recovers from an acute decompensation event.
Congestive heart failure is a chronic disease that affects an estimated 5 million people in the U.S. with a projected cost of $27.9 billion in 2005.
Publication:
U.S. Food and Drug Administration (FDA)
On the web:www.orqis.com
Advertise in this space for $10 per month.
Contact us today.
About Orqis Medical
Orqis Medical Corporation is a privately held clinical-stage medical device company that is investigating its discovery of a new, percutaneous approach to treat patients suffering from congestive heart failure. Founded in 1997, Orqis Medical is headquartered in Lake Forest, California. For more information, visit www.orqis.com.
Feedback
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
